WELLINGTON MANAGEMENT CO LLP 13D and 13G filings for Celldex Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 10:52 am Purchase |
2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX |
WELLINGTON MANAGEMENT CO LLP | 9,243,599 13.940% |
2,767,038 (+42.72%) |
Filing |
| 2024-02-08 10:11 am Purchase |
2023-12-29 | 13G | Celldex Therapeutics, Inc. CLDX |
WELLINGTON MANAGEMENT CO LLP | 6,476,561 11.840% |
1,695,064 (+35.45%) |
Filing |
| 2023-05-10 08:54 am Purchase |
2023-04-28 | 13G | Celldex Therapeutics, Inc. CLDX |
WELLINGTON MANAGEMENT CO LLP | 4,781,497 10.120% |
133,585 (+2.87%) |
Filing |
| 2023-02-06 2:49 pm Purchase |
2022-12-30 | 13G | Celldex Therapeutics, Inc. CLDX |
WELLINGTON MANAGEMENT CO LLP | 4,647,912 9.870% |
4,647,912 (New Position) |
Filing |